Lahore: Citi Pharma Limited has released its Annual Report for the fiscal year ending June 30, 2026, revealing a 6.5% increase in revenue to Rs. 14,004.6 million. The report, dated October 7, 2026, reflects the company's operations in a challenging economic environment marked by inflation, fluctuating exchange rates, and regulatory hurdles.

Citi Pharma Limited, a key player in the manufacturing and sale of pharmaceutical products, faced significant challenges due to inflationary pressures and increased financing and energy costs. Despite these obstacles, the demand for its products remained steady, supported by essential healthcare needs. The company focused on operational efficiency and cost management to navigate these hurdles.

According to information available from the Pakistan Stock Exchange (PSX), Citi Pharma's gross profit surged by 21.4% to Rs. 2,449.6 million, with the gross profit margin improving by 2.2 percentage points to 17.5%. This improvement stemmed from a reduction in raw-material consumption costs and an emphasis on operational efficiency. However, the profit before tax experienced a minor move, declining by 1.7% to Rs. 1,331.3 million, while profit after tax saw a big move, dropping 12.3% to Rs. 782.6 million.

Earnings per share decreased to Rs. 3.43 from Rs. 3.90 in the previous year, reflecting a 12.1% decline. The net profit margin also experienced a moderate move, decreasing by 1.2 percentage points to 5.6%.

The Board of Directors decided against recommending any dividend for the fiscal year, considering the company's profitability, cash generation, and future funding requirements. Citi Pharma remains committed to enhancing its manufacturing capabilities and optimizing its working capital.

The consolidated financial statements include the operations of Citi Veterinary Limited, a subsidiary involved in veterinary drugs. Citi Pharma holds 99.99% of Citi Veterinary Limited's shares, with the subsidiary's performance included in the group's financial statements.